

WEST Search History

DATE: Monday, December 08, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE;</i>			
<i>PLUR=YES; OP=ADJ</i>			
L13	L12 same procoagulant	33	L13
L12	L11 same (anti or antibody)	1267	L12
L11	factor adj (ix or ixa)	4047	L11
L10	L9 and l8 and l7 and l5	0	L10
L9	schwarz-'hans-peter'.in.	75	L9
L8	dorner-friedrich.in.	114	L8
L7	falkner-'falko-guenter'.in.	19	L7
L6	kerschbaumer-randolf.pn.	0	L6
L5	scheiflinger-friedrich.in.	10	L5
L4	193 adj ad3	1	L4
L3	198 adj ab2	0	L3
L2	193 adj k2	0	L2
L1	200119992.pn.	2	L1

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 15:29:39 ON 08 DEC 2003)

FILE 'DISSABS, IMOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX,
COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, OCEAN,
MEDICONF, PASCAL, PAPERCHEM2, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT,
ADISNEWS, ANABSTR, BIOBUSINESS, BIOCOMMERCE, ...' ENTERED AT 15:29:53 ON
08 DEC 2003

L1 38 S 193 (A) AD3 — SEQ ID No: 5 + 82
L2 3 S 198 (A) AB2 → SEQ ID No: 86
L3 38 S 193 (A) K2 → SEQ ID No: 6 + 84
L4 37 S HYBRIDOMA (S) (L1 OR L2 OR L3)
L5 37 DUP REM L4 (0 DUPLICATES REMOVED)
E SCHEIFLINGER FRIEDRICH?/AU
L6 63 S E1 OR E2
E KERSCHBAUMER-RANDOLF.IN.
E KERSCHBAUMER-RANDOLF?/AU
E KERSCHBAUMER RANDOLF?/AU
L7 28 S E1 OR E2 OR E4
E FALKNER 'FALKO-GUENTER'?/AU
L8 31 S E1 OR E2 OR E4
E DORNER FRIEDRICH?/AU
L9 407 S E1 OR E2
E SCHWARZ HANS PETER?/AU
L10 313 S E2
L11 6209 S (FACTOR (A) (IX OR IXA)) (S) (ANTI OR ANTIBOD?)
L12 241 S L11 (S) PROCOAGULANT
L13 177 DUP REM L12 (64 DUPLICATES REMOVED)

=>

WEST

Generate Collection

Print

L13: Entry 30 of 33

File: USPT

Feb 25, 1992

DOCUMENT-IDENTIFIER: US 5091363 A

**** See image for Certificate of Correction ****

TITLE: Agent for the therapy of factor VIII-resistant hemophilia A, and a process for the preparation thereof

CLAIMS:

6. The therapeutic agent prepared as claimed in claim 1 that has potent procoagulant action while containing no activated coagulation enzymes as shown by testing on chromogenic substrates for factor IIa and Xa; is capable of reducing the partial thromboplastin time of normal citrated human plasma and of plasma containing inhibitors of factor VIII:C; said procoagulant action is not impaired by the presence of antibodies against factor IX; and upon gel filtration on Sepharose CL 6B, the activity of the agent migrates in the exclusion volume, and the fractions with inhibitor activity contain phospholipids, von Willebrand antigen, the modified light chain of factor VIII:C, factor IX, a component having a molecular weight of 100 kD, and antithrombin III.